The article by Page1 on the treatment of 18 patients with lupus erythematosus with quinacrine hydrochloride (Atabrine) has initiated widespread interest in the United States regarding this subject. As early as 1940, Prokoptchouk2 reported the use of quinacrine (Acrichin) in 35 patients with lupus erythematosus and was impressed with its effectiveness. Popoff and Kutinscheff3 observed remission of lupus erythematosus in six patients treated with quinacrine in 1941. Krynski4 treated six patients during the period 1940-1945. Pseudoicterus developed in one patient, and another showed a temporary psychic disturbance. He concluded that the method was effective but that the high incidence of side-reactions probably made its more general usage unwarranted. It has since been shown that the American product Atabrine (quinacrine hydrochloride, U. S. P.) probably is less toxic and produces fewer side-effects than Acrichin the Russian product or its German analogue Atabrin.5 Bispham,6 in a
Cole HN, Heights S, Chivington PV, Cole HN, Driver JR. TREATMENT OF CHRONIC DISCOID LUPUS ERYTHEMATOSUS WITH QUINACRINE. JAMA. 1953;153(17):1515–1516. doi:10.1001/jama.1953.02940340017006
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: